Skip to content
MARKETS / BALCAO / VCNX
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Vaccinex, Inc. VCNX

8 fiscal years on record · USD · FY2024 reported · SEC filings only
$601,000
▲ 5.4% YoY
$-18.6M
$-16.2M
In brief

What this company does

We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. We have used our SEMA4D antibody platform and our extensive knowledge of SEMA4D biology to develop our lead product candidate, pepinemab, an antibody that we believe utilizes novel mechanisms of action. Our lead platform technology is our SEMA4D antibody platform which includes our lead product candidate, pepinemab, which is currently in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer, through our efforts or through investigator-sponsored trials. Our ActivMAb® antibody discovery platform is a proprietary human antibody discovery platform based on a novel method for expressing and presenting complex multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses. Pepinemab is a humanized monoclonal antibody that binds and blocks the signaling activity of SEMA4D. VX5 was generated by our ActivMAb platform for preclinical development related to autoimmune disorders.

Written from the business description in VACCINEX, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 15 April 2025. Every sentence was checked against that document before publication.

Growth
USD 601,000.00
Revenue, FY2024 · full 8-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.6 · Net income -18.6
-20M20172018201920202021202220232024
Compound annual growth
−12.6%
+2.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +2.8% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−3100 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -3117.3% · Net -3100.5%
-10000%-20000%20172018201920202021202220232024
ROE

No chart to show — the reason differs by year; see each year in the table below.

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -16.2
-20M20172018201920202021202220232024

Total assetsUSD 2.6M
CashUSD 1.1M
Gross debtUSD 25,000.00
Net debtUSD -1.1M
Current ratio0.50×

Not available: we don't have the shareholders' equity figure for this period.

The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20242023202220212020201920182017
Revenue $B0.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−8.88−43.68−98.05−0.78−1.54−2.47−5.65−19.90
Dividend / sh $········
Payout %········
ROE %··−267.3·····
Shares out B0.000.000.000.030.020.010.010.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 1 divergences in 32 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 59 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures1 divergent
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image